## **Neuro-Oncology**

26(10), 1947, 2024 | https://doi.org/10.1093/neuonc/noae151 | Advance Access date 21 August 2024

## Corrigendum to: LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement

В

LY6K

p-ERK1/2

**ERK1/2** 

p-AKT

GAPDH

SB590885

PD98059

p-ERK1/2

ERK1/2

p-AKT

AKT

LY6K

AKT

**GSC528** 

sh-L + LY6

-26

42

42

52

-52

34

26

12

42

52

52

-140

D

sh-LY6k

GSC30

Ctrl

This is a corrigendum to: Namratha G Sastry, Xuechao Wan, Tianzhi Huang, Angel A Alvarez, Rajendra P Pangeni, Xiao Song, Charles David James, Craig M Horbinski, Cameron W Brennan, Ichiro Nakano, Bo Hu, Shi-Yuan Cheng, LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement, Neuro-Oncology, Volume 22, Issue 9, September 2020, Pages 1315-1326, https://doi. org/10.1093/neuonc/noaa032

In April 2024, concerns were raised on PubPeer about Figure 3A. The Journal subsequently contacted the corresponding author for an explanation. Following the authors' checks, the Journal has agreed that they may amend the immunoblot data for GSC30 (third and fourth column on the right) shown

A

С

LY6K

p-ERK1/2

**ERK1/2** 

p-AKT

GAPDH

p-ERK1/2

ERK1/2

p-AKT

p-EGFR

AKT

AKT

EGF LY6K

GSC83

1 Y6K

Ctrl

in Fig. 3A, which were found to be erroneous. In the originally published version, the lane of p-ERK1/2 was mistakenly used twice.

In the corrected Figure 3A, the authors have replaced the data from the two rightmost columns using the original data from experiments that were performed during the same period as the original data were produced. The new figure panel is shown here.

The authors and editors agree that the new data do not impact the results or conclusions of the published article, and the authors have apologized for mistakenly uploading the wrong image originally.

The corrected Figure 3 is given below:

26

42

42


52

52

34

52

U87



<sup>©</sup> The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com.